Why the study?
Does ticagrelor improve inflammatory parameters (NLR, MHR, PLR, and SII) in PCI-treated ACS patients compared to clopidogrel?
Does ticagrelor improve inflammatory parameters (NLR, MHR, PLR, and SII) in PCI-treated ACS patients compared to clopidogrel?
Ticagrelor may offer additional anti-inflammatory benefits over clopidogrel in patients with acute coronary syndrome undergoing PCI.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for ticagrelor’s anti-inflammatory effects in ACS; does not support practice change pending RCTs.
NLR, MHR, PLR, and SII levels were lower in ACS patients treating with ticagrelor. Ticagrelor may improve these inflammatory parameters in percutaneous coronary intervention (PCI)-treated ACS patients compared to clopidogrel.
No takes yet. Share an insight, caveat, or question.
Adalı et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: